Adding trastuzumab to carboplatin and paclitaxel improves overall survival in advanced-stage HER2/NEU overexpressing uterine serous carcinoma or carcinosarcoma

被引：0
|
作者：
Lu, Ting-Fang [1 ]
Lou, Sun [1 ]
Shih, Yu-Hsiang [1 ]
Chen, Yen-Fu [1 ]
Fan, Chun Ting [1 ]
Wang, Shao-Jing [1 ]
Hsu, Shih-Tien [1 ]
Liu, Chin-Ku [1 ]
Hwang, Sheau-Feng [1 ]
Lu, Chien-Hsing [1 ]
机构：
[1] Taichung Vet Gen Hosp, Obstet & Gynecol Dept, Taichung, Taiwan
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR017
引用
收藏
页码：A45 / A46
页数：2
相关论文
共 50 条
  • [41] Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
    Santin, AD
    Bellone, S
    Van Stedum, S
    Bushen, W
    De Las Casas, LE
    Korourian, S
    Tian, E
    Roman, JJ
    Burnett, A
    Pecorelli, S
    GYNECOLOGIC ONCOLOGY, 2005, 98 (01) : 24 - 30
  • [42] Phosphorylated HER3 levels associated with trastuzumab resistance in HER2 gene amplified uterine serous carcinoma xenograft tumors
    Hernandez, Silvia F.
    DiGloria, Celeste
    Groeneweg, Jolijn
    Borger, Darrell
    Foster, Rosemary
    Rueda, Bo
    Growdon, Whitfield
    CANCER RESEARCH, 2015, 75
  • [43] Survival comparison of primary cytoreductive surgery versus interval cytoreductive surgery for the treatment of advanced-stage uterine serous carcinoma
    Roy, Molly
    Barkdull, Savannah
    Verna, Ayita
    Pinto, Andre
    Siemon, John
    Tabuyo-Martin, Angel
    Samuel, David
    Schlumbrecht, Matthew
    Huang, Marilyn
    Sinno, Abdulrahman
    Pearson, Joseph
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S283 - S284
  • [44] Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer.
    Robert, N
    Leyland-Jones, B
    Asmar, L
    Belt, R
    Ilegbodu, D
    Loesch, D
    Raju, R
    Valentine, E
    Sayre, R
    Albain, K
    Cobleigh, M
    McCullough, C
    Fuchs, L
    Slamon, D
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S37 - S37
  • [45] Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
    Han, Hye-Suk
    Kim, Jin-Soo
    Park, Jin Hyun
    Jeon, Yoon Kyung
    Lee, Keun-Wook
    Oh, Do-Youn
    Kim, Jee Hyun
    Park, So Yeon
    Im, Seock-Ah
    Kim, Tae-You
    Park, In Ae
    Bang, Yung-Jue
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2009, 24 (05) : 910 - 917
  • [46] Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
    Gomez-Martin, Carlos
    Carlos Plaza, Jose
    Pazo-Cid, Roberto
    Salud, Amonieta
    Pons, Francesc
    Fonseca, Paula
    Leon, Ana
    Alsina, Maria
    Visa, Laura
    Rivera, Fernando
    Carmen Galan, M.
    del Valle, Elena
    Vilardell, Felipe
    Iglesias, Mar
    Fernandez, Soledad
    Landolfi, Stefania
    Cuatrecasas, Miriam
    Mayorga, Marta
    Jose Ponles, M.
    Sanz-Moncasi, Pilar
    Montagut, Clara
    Garralda, Elena
    Rojo, Federico
    Hidalgo, Manuel
    Lopez-Rios, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) : 4445 - +
  • [47] Preoperative trastuzumab (T) and paclitaxel (P) for HER2 overexpressing (HER2+) stage II/III breast cancer: clinical, pathological and serological findings.
    Burstein, HJ
    Nunes, RA
    Lester, S
    Kaelin, CM
    Harris, LN
    Winer, EP
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 298 - 298
  • [48] Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
    Kerklaan, Bojana Milojkovic
    Dieras, Veronique
    Le Tourneau, Christophe
    Mergui-Roelvink, Marja
    Huitema, Alwin D. R.
    Rosing, Hilde
    Beijnen, Jos H.
    Marreaud, Sandrine
    Govaerts, Anne-Sophie
    Piccart-Gebhart, Martine J.
    Schellens, Jan H. M.
    Awada, Ahmad
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 53 - 62
  • [49] Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
    Bojana Milojkovic Kerklaan
    Veronique Diéras
    Christophe Le Tourneau
    Marja Mergui-Roelvink
    Alwin D. R. Huitema
    Hilde Rosing
    Jos H. Beijnen
    Sandrine Marreaud
    Anne-Sophie Govaerts
    Martine J. Piccart-Gebhart
    Jan H. M. Schellens
    Ahmad Awada
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 53 - 62
  • [50] Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma:: prolonged survival with combined chemotherapy and trastuzumab
    Lazaro, Alicia
    Cassinello, Javier
    Amoros, Almudena
    Heredia, Miriam
    Lopez-Alfonso, Ana
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (09): : 587 - 590
12345